Quick Answer
Actinium Pharmaceuticals, Inc. reported Total Revenue of $90.0 thousand for fiscal year 2025.
Actinium Pharmaceuticals, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $90.0K | +11.1% |
| 2023 | $81.0K | -92.1% |
| 2022 | $1.03M | -10.0% |
| 2021 | $1.14M | — |
| 2011 | $0.00 | — |
| 2010 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $90.0K | — | +100.0% |
| September 30, 2022 | $45.0K | -80.7% | +0.0% |
| June 30, 2022 | $45.0K | -83.1% | -95.2% |
| March 31, 2022 | $940.0K | +51.1% | +303.4% |
| September 30, 2021 | $233.0K | — | -12.4% |
| June 30, 2021 | $266.0K | — | -57.2% |
| March 31, 2021 | $622.0K | — | — |
| March 31, 2012 | $0.00 | — | — |
- Actinium Pharmaceuticals, Inc. showed an increase of +11.1% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Actinium Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: